TRENDING :  Market Movers  |  Top 50   AAPL (0%)    TSLA (0%)    TVIX (0%)    RIOT (0%)    QURE (0%)    QQQ (0%)    QCOM (0%)    PSTG (0%)    PEI (0%)    PAH (0%)    MCD (0%)    KO (0%)    JPM (0%)    IVC (0%)    IMDZ (0%)    GS (0%)    GOOGL (0%)    FDX (0%)    FCEL (0%)    FB (0%)    EA (0%)    CRM (0%)    CBS (0%)    BILI (0%)    BIDU (0%)

 IRWD - Ironwood Pharmaceuticals

$14.18 [0][0%]

Next Earnings



Trade Idea »


Quarterly Rating Chart


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $13.00
Low $13.00
Average $13.00
Current $14.18

CompanyAnalyst NamePT ActionActionRatingTargetDate
JP MorganRaisesUpgradesHold$13.0001/24/19
*Last 90 days


No recommendations found.

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.


Service NameTrader% Success
Alpha Swing TradesJonathan69.00 %Follow


Ironwood (IRWD) Q4 Earnings & Revenues Beat, Shares Rise

Ironwood Pharmaceuticals Inc IRWD incurred fourth quarter 2018 adjusted loss of 2 cents per share narrower than the Zacks Consensus Estimate of a loss of 17 cents as well as the loss of 14 cents in the year ago period Total revenues in the fourth quarter were 130 7 million reflecting

Why Ironwood's Shares Climbed 11.7% on Wednesday

What happened After reporting fourth quarter financial results that were better than expected on both the top and bottom line and updating investors on its plans to split into two companies Ironwood Pharmaceuticals NASDAQ IRWD surged 11 7 higher today So

Ironwood Pharmaceuticals Inc (IRWD) Q4 2018 Earnings Conference Call Transcript

Image source The Motley Fool Ironwood Pharmaceuticals Inc NASDAQ IRWD Q4 160 2018 Earnings Conference Call Feb 13 2019 8 30 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared

Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Tops Revenue Estimates

Ironwood Pharmaceuticals IRWD came out with a quarterly loss of 0 02 per share versus the Zacks Consensus Estimate of a loss of 0 17 This compares to loss of 0 14 per share a year ago These figures are adjusted for non recurring items This quarterly report represents an earnings

Earnings Preview: Ironwood Pharmaceuticals (IRWD) Q4 Earnings Expected to Decline

Wall Street expects a year over year decline in earnings on lower revenues when Ironwood Pharmaceuticals IRWD reports results for the quarter ended December 2018 While this widely known consensus outlook is important in gauging the company s earnings picture a powerful factor that could

Allergan (AGN) Q4 Earnings Beat Estimates, 2019 View Tepid

Allergan plc s AGN fourth quarter 2018 earnings came in at 4 29 per share which beat the Zacks Consensus Estimate of 4 15 However earnings fell 11 7 year over year mainly due to lower revenues Revenues came in at 4 08 billion which exceeded the Zacks Consensus Estimate of 3

Ironwood Commences Phase I Study on IW-6463 for CNS Disorders

Ironwood Pharmaceuticals Inc IRWD announced that it has initiated a phase I study on its orally administered central nervous system CNS penetrant soluble guanylate cyclase sGC stimulator IW 6463 The candidate is currently being evaluated for the treatment of serious and orphan